Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 04/28 04:59:57 pm
265.7 DKK   -0.04%
04/28NOVO NORDISK A/ : quaterly earnings release
04/24 NOVO NORDISK A/ : - Reduction of the share capital
04/24 NOVO NORDISK A/ : - Share repurchase programme
News SummaryMost relevantAll newsSector newsTweets 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK A/S
04/28NOVO NORDISK A/S : quaterly earnings release
04/27 NOVO NORDISK A/S : New Data from Keio University Illuminate Findings in Anterior..
04/24 NOVO NORDISK A/S : - Reduction of the share capital
04/24 NOVO NORDISK A/S : - Share repurchase programme
04/22 NOVO NORDISK A/S : Leo Club, Novo Nordisk help intellectually challenged kids
04/21 XOMA CORPORATION (NASDAQ : XOMA) Files An 8-K Termination of a Material Definiti..
04/21 NOVO NORDISK A/S : - Reduction of the share capital
04/20 NOVOZYMES A/S : Researchers Submit Patent Application, "Subtilase Variants", for..
04/20 NOVO NORDISK A/S : Patent Issued for Automatic Injection Device with a Top Relea..
04/20 NOVO NORDISK A/S : Researchers from Novo Nordisk Discuss Findings in Proinsulin ..
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/29 How To Research And Invest In Global Stocks The Smart Way
04/28 SNIPPETS ROUNDUP : Sanofi Diabetes Disappointment, And Amgen Pullback Signals CG..
04/28 Calling All Heart Docs - Your Diabetes Drugs Need You
04/27 Current Trades
04/26 Lilly Assures Market As Diabetes Stumbles
Financials ( DKK)
Sales 2017 116 133 M
EBIT 2017 49 982 M
Net income 2017 37 846 M
Finance 2017 15 600 M
Yield 2017 2,85%
P/E ratio 2017 17,37
P/E ratio 2018 15,63
EV / Sales 2017 4,36x
EV / Sales 2018 4,15x
Capitalization 521 453 M
More Financials
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 32
Average target price 270  DKK
Spread / Average Target 1,7%
Consensus details
EPS Revisions
More Estimates Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S0.67%76 508
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.31%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results